Viracta Therapeutics, Inc. (NASDAQ: VIRX) reported Q2 EPS of ($0.25), $0.12 better than the analyst estimate of ($0.37).

For earnings history and earnings-related data on Viracta Therapeutics, Inc. (VIRX) click here.